Sanctuary Advisors LLC Takes $4.72 Million Position in Kenvue Inc. $KVUE

Sanctuary Advisors LLC acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 247,012 shares of the company’s stock, valued at approximately $4,720,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Kenvue in the 2nd quarter worth approximately $2,882,279,000. Norges Bank bought a new stake in Kenvue during the 4th quarter valued at $756,862,000. Independent Franchise Partners LLP raised its holdings in Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after acquiring an additional 17,343,785 shares during the period. Sculptor Capital LP lifted its position in shares of Kenvue by 1,023.5% during the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock worth $222,289,000 after acquiring an additional 11,739,328 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Kenvue during the second quarter worth $192,080,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $19.41 on Tuesday. The firm has a market capitalization of $37.27 billion, a PE ratio of 22.30, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.63. The business’s 50-day moving average price is $19.08 and its 200-day moving average price is $18.21.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the firm posted $0.29 earnings per share. The company’s revenue was up 3.0% compared to the same quarter last year. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KVUE. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. UBS Group lowered their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Barclays raised their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.